The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis

Aladul, Mohammed I.; Fitzpatrick, R; Chapman, Stephen

doi:10.1016/j.sapharm.2018.05.009

Cited by 37 publications

(34 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They account for 9 of the top 10 biologics in the global market [11]. Health economic evaluations and budget impact studies of biosimilars of these agents can lead to significant cost savings and these studies have shown that biosimilars of TNF-α inhibitors are cost-effective in the perspectives of the health systems that assessed them [31][32][33][34][35][36][37].…”

Section: Discussionmentioning

confidence: 99%

Health technology assessment of biosimilars worldwide: a scoping review

Ascef

Lopes

Soárez

2020

Health Res Policy Sys

View full text Add to dashboard Cite

Background: Health technology assessment (HTA) should provide an assessment of a technology's effects on health and of the related social, economic, organisational and ethical issues. HTA reports on biosimilars can specifically assess their immunogenicity, their extrapolation to one or more conditions, and the risks of interchangeability and substitution. We aimed to complete a scoping review within the context of HTA organisations to synthesise HTA reports on biosimilars and to map the extension, scope and methodological practices. Main body: A scoping review methodology was applied. The sources for biosimilars HTA reports were database searches and grey literature from HTA organisation websites up to June 2019. HTA reports of biosimilars were classified as full HTA, mini-HTA or rapid reviews. Data were extracted and recorded on a calibrated predefined data form. We identified 70 HTA reports of biosimilars of 16 biologic products (65.71% in 2015-2018) produced by 13 HTA organisations from 10 countries; 2 full HTAs, 4 mini-HTAs and 64 rapid reviews met the inclusion criteria. Almost all the rapid reviews gave no information regarding any evidence synthesis method and approximately half of the rapid reviews did not appraise the risk of bias of primary studies or the overall quality of evidence. All full-HTAs and mini-HTAs addressed organisational, ethical, social and legal considerations, while these factors were assessed in less than half of the rapid reviews. The immunogenicity and extrapolation of one or more conditions were often considered. The majority of full-HTAs and mini-HTAs contained an assessment of switching and a discussion of an educational approach about biosimilars. No HTA report rejected the adoption/reimbursement of the biosimilar assessed. Conclusion: HTA of biosimilars are emerging in the context of HTA organisations and those that exist often duplicate reports of the same biosimilar. Most HTA reports of biosimilars do not conduct a systematic literature review or consider economic issues. No report has rejected the adoption/reimbursement of biosimilars. There is a need to standardise the minimum criteria for the development of HTA on biosimilars to ensure a better understanding and better decision-making.

show abstract

Section: Discussionmentioning

confidence: 99%

Health technology assessment of biosimilars worldwide: a scoping review

Ascef

Lopes

Soárez

2020

Health Res Policy Sys

View full text Add to dashboard Cite

show abstract

“…1,2 Cost-effectiveness, prescription patterns, dispensing practices and patients' belief about efficacy and safety of biosimilars are among the vital factors which are expressively essential to understand. 10,11 Saudi Food and Drug Authority (SFDA) is mainly responsible for the approval and availability of all drugs to use in Saudi Arabia. 12 In 2010, the SFDA developed and published the first guidelines regarding the registration of biosimilars in the country.…”

Section: Introductionmentioning

confidence: 99%

Physicians’ Knowledge and Awareness about Biosimilars in Saudi Arabia: What is Imperative to Know ??

Almalki¹,

Iqbal²,

Alossaimi³

et al. 2020

JYP

View full text Add to dashboard Cite

Objectives: This study determined the current awareness and knowledge among physicians about biosimilars in Saudi Arabia. Methods: This study used a cross-sectional study design and data were acquired by the convenience sampling method. The research tool was self-developed, prevalidated and self-administered to achieve the sample size. The physicians from various parts of the country participated in the study. Both, inferential statistics with the help of descriptive statistics were applied using the Statistical Package for Social Sciences (SPSS) version 24.0 and Microsoft Excel. A p-value <0.05 was considered statistically significant. Results: A total of 105 practicing physicians throughout the country participated in the study. The majority of the participants were well informed and had adequate knowledge and awareness about numerous aspects of biosimilars except for the local healthcare policies and payer policies, where around half of them very aware of them. Statistically, a non-significant association (p-value >0.05) was observed. Conclusion: It is concluded that the study physicians had adequate knowledge and awareness about biosimilars in Saudi Arabia. Statistically, a non-significant association (p <0.05) was observed between adequate and inadequate knowledge among the studied physicians in Saudi Arabia.

show abstract

“…A recent budget impact analysis in the UK estimated that the entry of new anti-TNFs (tumor necrosis factors) would result in a cumulative savings of £285 million by 2020. 33 Hospitals and department negotiations with commissioners about ‘gain share’ could either enhance or delay the uptake of biosimilars. If gain share was possible this would incentivise HCPs to use these biosimilars if they were offered to the department.…”

Section: Discussionmentioning

confidence: 99%

Healthcare professionals’ perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study

2018

Self Cite

View full text Add to dashboard Cite

ObjectiveTo investigate UK healthcare professionals’ perceptions and perspectives towards biosimilar infliximab, etanercept and insulin glargine and the potential barriers and facilitators to their prescribing.DesignA cross-sectional qualitative study design was used.SettingFive hospitals within the West Midlands area in UK.Interventions30 min face-to-face, semistructured interviews of healthcare professionals.Participants22 healthcare professionals (consultants, nurses and pharmacists) participated in the semistructured interviews.OutcomesParticipants’ opinion and attitudes about biosimilars and the barriers and facilitators to the prescribing of infliximab, etanercept and insulin glargine biosimilars in gastroenterology, rheumatology and diabetology specialties.ResultsThis study showed that UK healthcare professionals had good knowledge of biosimilars and were content to initiate them. Healthcare professionals disagreed with biosimilar auto-substitution at pharmacy level and multiple switching. Subtle differences among healthcare professionals were identified in the acceptance of switching stable patients, indication extrapolation and cost savings sharing.ConclusionSafety and efficacy concerns, patients’ opinion and how cost savings were shared were the identified barriers to considering prescribing biosimilars. Real-life data and financial incentives were the suggested facilitators to increase biosimilar utilisation.

show abstract

The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis

Cited by 37 publications

References 23 publications

Health technology assessment of biosimilars worldwide: a scoping review

Health technology assessment of biosimilars worldwide: a scoping review

Physicians’ Knowledge and Awareness about Biosimilars in Saudi Arabia: What is Imperative to Know ??

Healthcare professionals’ perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study

Contact Info

Product

Resources

About